Article
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 5 2085
respectively). We thank Thomas Zillinger, student of mole-
cular biomedicine, Samer Al-Helly and Anja Kliem, students
of pharmacy, and Florian Hoss, high school graduatestudent,
for synthesizing some of the compounds. Karen Schmeling
and Dr. Petra Hillmann are acknowledged for testing selected
compounds at P2Y receptors.
quercetin in the human U138MG glioma cell line. Biochim. Bio-
phys. Acta 2007, 1770, 1352–1359.
(15) Zhi, X.; Chen, S.; Zhou, P.; Shao, Z.; Wang, L.; Ou, Z.; Yin, L.
RNA interference of ecto-50-nucleotidase (CD73) inhibits human
breast cancer cell growth and invasion. Clin. Exp. Metastasis 2007,
24, 439–448.
(16) (a) Crane, J. K.; Naeher, T. M.; Shulgina, I.; Zhu, C.; Boedeker,
E. C. Effect of zinc in enteropathogenic Escherichia coli infection.
Infect. Immun. 2007, 75, 5974–5984. (b) Alam, M. S.; Kurtz, C. C.;
Rowlett, R. M.; Reuter, B. K.; Wiznerowicz, E.; Das, S.; Linden, J.;
Crowe, S. E.; Ernst, P. B. CD73 is expressed by human regulatory T
helper cells and suppresses proinflammatory cytokine production and
Helicobacter felis-induced gastritis in mice. J. Infect. Dis. 2009, 199,
494–504.
1
Supporting Information Available: Analytical data and H
NMR, 13C NMR, and LC-MS spectra of the newly synthesized
anthraquinone derivatives. This material is available free of
(17) Peng, Z.; Fernandez, P.; Wilder, T.; Yee, H.; Chiriboga, L.; Chan,
E. S.; Cronstein, B. N. Ecto-50-nucleotidase (CD73)-mediated
extracellular adenosine production plays a critical role in hepatic
fibrosis. FASEB J. 2008, 22, 2263–2272.
References
(1) (a) Burnstock, G. Physiology and pathophysiology of purinergic
neurotransmission. Physiol. Rev. 2007, 87, 659–797. (b) Burnstock,
G. Pathophysiology and therapeutic potential of purinergic signaling.
Pharmacol. Rev. 2006, 58, 58–86. (c) M€uller, C. E. P2-pyrimidinergic
receptors and their ligands. Curr. Pharm. Des. 2002, 8, 2353–2369. (d)
Brunschweiger, A.; M€uller, C. E. P2 receptors activated by uracil
nucleotides;An update. Curr. Med. Chem. 2006, 13, 289–312.
(2) (a) Bender, E.; Buist, A.; Jurzak, M.; Langlois, X.; Baggerman, G.;
Verhasselt, P.; Ercken, M.; Guo, H. Q.; Wintmolders, C.; Van, d.
W.I.; Van, O. I.; Schoofs, L.; Luyten, W. Characterization of an
orphan G protein-coupled receptor localized in the dorsal root
ganglia reveals adenine as a signaling molecule. Proc. Natl. Acad.
Sci. U.S.A. 2002, 99, 8573–8578. (b) Gorzalka, S.; Vittori, S.; Volpini,
R.; Cristalli, G.; von K€ugelgen, I.; M€uller, C. E. Evidence for the
Functional Expression and Pharmacological Characterization of
Adenine Receptors in Native Cells and Tissues. Mol. Pharmacol.
2005, 67, 955–964. (c) von K€ugelgen, I.; Schiedel, A. C.; Hoffmann,
K.; Alsdorf, B. A.; Abdelrahman, A.; M€uller, C. E. Cloning and
Functional Expression of a Novel Gi Protein-Coupled Receptor for
Adenine from Mouse Brain. Mol. Pharmacol. 2008, 73, 469–477. (d)
Borrmann, T.; Abdelrahman, A.; Volpini, R.; Lambertucci, C.; Alksnis,
E.; Gorzalka, S.; Knospe, M.; Schiedel, A. C.; Cristalli, G.; M€uller, C. E.
Structure-Activity Relationships of Adenine and Deazaadenine Deri-
vatives as Ligands for Adenine Receptors, a New Purinergic Receptor
Family. J. Med. Chem. 2009, 52, 5974–5989.
(18) (a) Kawashima, Y.; Nagasawa, T.; Ninomiya, H. Contribution of
ecto-50-nucleotidase to the inhibition of platelet aggregation by
€
human endothelial cells. Blood 2000, 96, 2157–2162. (b) Strater, N.
Ecto-50-nucleotidase: Structure function relationships. Purinergic Sig-
nalling 2006, 2, 343–350.
(19) Uchino, K.; Matsuo, T.; Iwamoto, M.; Tonosaki, Y.; Fukuchi, A.
New 50-nucleotidase inhibitors, NPF-86IA, NPF-86IB, NPF-
86IIA, and NPF-86IIB from Areca catechu; Part I. Isolation and
biological properties. Planta Med. 1988, 54, 419–422.
(20) Braganhol, E.; Tamajusuku, A. S.; Bernardi, A.; Wink, M. R.;
Battastini, A. M. Ecto-50-nucleotidase/CD73 inhibition by quer-
cetin in the human U138MG glioma cell line. Biochim. Biophys.
Acta 2007, 1770, 1352–1359.
(21) Bo, X.; Fischer, B.; Maillard, M.; Jacobson, K. A.; Burnstock, G.
Comparative studies on the affinities of ATP derivatives for P2X-
purinoceptors in rat urinary bladder. Br. J. Pharmacol. 1994, 112,
1151–1159.
€
(22) (a) Bultmann, R.; Starke, K. P2-purinoceptor antagonists discri-
minate three contraction mediating receptors for ATP in rat vas
deferens. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1994, 349,
€
74–80. (b) Tuluc, F.; B€ultmann, R.; Glanzel, M.; Frahm, A. W.; Starke,
K. P2-receptor antagonists: IV. Blockade of P2-receptor subtypes and
ecto-nucleotidases by compounds related to reactive blue 2. Naunyn-
Schmiedeberg’s Arch. Pharmacol. 1998, 357, 111–120.
(23) Brake, A. J.; Wagenbach, M. J.; Julius, D. New structural motif for
ligand-gated ion channels defined by an ionotropic ATP receptor.
Nature 1994, 371, 519–523.
(3) Burnstock, G. Purinergic cotransmission. Brain Res. Bull. 1999, 50,
355–357.
(4) Zimmermann, H.; Braun, N. Ecto-nucleotidases: Molecular struc-
tures, catalytic properties, and functional roles in the nervous
system. Prog. Brain Res. 1999, 120, 371–385.
(24) (a) Simon, J.; Webb, T. E.; King, B. F.; Burnstock, G.; Barnard,
E. A. Characterisation of a recombinant P2Y purinoceptor. Eur. J.
Pharmacol. 1995, 291, 281–289. (b) Chang, K.; Hanoka, K.; Kumada,
M.; Takuwa, Y. Molecular cloning and functional analysis of a novel P2
nucleotide receptor. J. Biol. Chem. 1995, 270, 26152–26158.
(25) Communi, D.; Parmentier, M.; Boeynaems, J.-M. Cloning, func-
tional expression and tissue distribution of the human P2Y6
receptor. Biochem. Biophys. Res. Commun. 1996, 222, 303–308.
(26) Communi, D.; Robaye, B.; Boeynaems, J.-M. Pharmacological
characterization of the human P2Y11 receptor. Br. J. Pharmacol.
1999, 128, 1199–1206.
(27) Michel, A. D.; Grahames, C. B. A.; Humphrey, P. P. A. Functional
characterization of P2 purinoceptors in PC12 cells by measurement
of radiolabelled calcium influx. Naunyn-Schmiedeberg’s Arch.
Pharmacol. 1996, 354, 562–571.
(28) Seguela, P.; Haghigi, A.; Soghommonian, J.-J.; Cooper, E. A novel
neuronal P2X ATP receptor ion channel with widespread distribu-
tion in the brain. J. Neurosci. 1996, 15, 448–455.
ꢀ
(5) Kukulski, F.; Levesque, S. A.; Lavoie, E. G.; Lecka, J.; Bigonnesse,
ꢀ
F.; Knowles, A. F.; Robson, S. C.; Kirley, T. L.; Sevigny, J.
Comparative hydrolysis of P2 receptor agonists by NTPDases 1,
2, 3, and 8. Purinergic Signalling 2005, 1, 193–204.
(6) Zimmermann, H. 50-nucleotidase: Molecular structure and func-
tional aspects. Biochem. J. 1992, 285, 345–365.
(7) Zimmermann, H. Extracellular metabolism of ATP and other
nucleotides. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2000, 362,
299–309.
(8) Napieralski, R.; Kempkes, B.; Gutensohn, W. Evidence for co-
ordinated induction and repression of ecto-50-nucleotidase (CD73)
and the A2A adenosine receptor in a human B cell line. Biol. Chem.
Hoppe-Seyler 2003, 384, 483–487.
(9) Goding, J. W.; Grobben, B.; Slegers, H. Physiological and patho-
physiological functions of the ecto-nucleotide pyrophosphatase/
phosphodiesterase family. Biochim. Biophys. Acta 2003, 1638,
1–19.
(10) Sadej, R.; Spychala, J.; Skladanowski, A. C. Expression of ecto-
50-nucleotidase (eN, CD73) in cell lines from various stages of
human melanoma. Melanoma Res. 2006, 16, 213–222.
(11) Resta, R.; Yamashita, Y.; Thompson, L. F. Ecto-enzyme and
signaling functions of lymphocyte CD73. Immunol. Rev. 1998,
161, 95–109.
(29) Webb, T. E.; Feolde, E.; Vigne, P.; Neary, J. T.; Runberg, A.;
Frelin, C.; Barnard, E. A. The P2Y purinoceptor in rat brain
microvascular endothelial cells couple to inhibition of adenylate
cyclase. Br. J. Pharmacol. 1996, 119, 1385–1392.
€
€
(30) Glanzel, M.; Bultmann, R.; Starke, K.; Frahm, A. W. Structure-
activity relationships of novel P2-receptor antagonists structurally
related to Reactive Blue 2. Eur. J. Med. Chem. 2005, 40, 1262–1276.
€
€
(31) Glanzel, M.; Bultmann, R.; Starke, K.; Frahm, A. W. Constitu-
tional isomers of Reactive Blue 2;Selective P2Y-receptor antago-
nists? Eur. J. Med. Chem. 2003, 38, 303–312.
(12) Spychala, J. Tumor-promoting functions of adenosine. Pharmacol.
Ther. 2000, 87, 161–173.
(13) (a) Mikhailov, A.; Sokolovskaya, A.; Yegutkin, G. G.; Amdahl,
H.; West, A.; Yagita, H.; Lahesmaa, R.; Thompson, L. F.;
Jalkanen, S.; Blokhin, D.; Eriksson, J. E. CD73 participates in
cellular multiresistance program and protects against TRAIL-
(32) Weyler, S.; Baqi, Y.; Hillmann, P.; Kaulich, M.; Hunder, A. M.;
€
€
Muller, I. A.; Muller, C. E. Combinatorial synthesis of anilinoan-
thraquinone derivatives and evaluation as non nucleotide-derived
P2Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 223–
227.
ꢀ
induced apoptosis. J. Immunol. 2008, 181, 464–475. (b) Ujhazy, P.;
Berleth, E. S.; Pietkiewicz, J. M.; Kitano, H.; Skaar, J. R.; Ehrke, M. J.;
Mihich, E. Evidence for the involvement of ecto-50-nucleotidase
(CD73) in drug resistance. Int. J. Cancer 1996, 68, 493–500.
€
€
€
(33) Baqi, Y.; Atzler, K.; Kose, M.; Glanzel, M.; Muller, C. E.
High-Affinity, Non-Nucleotide-Derived Competitive Antago-
nists of Platelet P2Y12 Receptors. J. Med. Chem. 2009, 52, 3784–
3793.
(14) Braganhol, E.; Tamajusuku, A. S.; Bernardi, A.; Wink, M. R.;
Battastini, A. M. Ecto-50-nucleotidase/CD73 inhibition by